April 17, 2017. Beijing, China.
Curelong (Beijing) Pharmaceutical Co., Ltd. and Beijing Daxing District Government officially signed four agreements: Framework Agreement, Lease Agreement, Supplementary Agreement, and Property Service Agreement, marking the settlement of Curelong’s Nanomedicine Industrial Park (CNIP) at Zhongguancun Daxing Bio-Pharmaceutical Industry Base (DBPIB). CNIP is the first nanomedicine base in the world that combines internal nanotechnology innovation, nanomedicine research development, external collaboration and incubation, clinical research, international drug application, and market development.
Kamdeepak capsule viagra 50mg no prescription is one of the best herbal treatment for leaking of semen. Silagra is the generic replica of the branded on line levitra purchased here is. Chiropractic is an area in health care that aims to ordering levitra from canada correct vertebral subluxations. Spam is a problem that faces viagra online http://new.castillodeprincesas.com/directorio/seccion/fotografia/ most people with email addresses today. Nanomedicine development combines interdisciplinary cutting-edge sciences including nanotechnology, nano-materials, pharmaceuticals, and clinics. Curelong has a world class nanomedicine R&D team along with the most advanced proprietary nanotechnology and strong pipelines. After thorough evaluations, Curelong finally decided to land at DBPIB. “We recognize that Beijing Daxing District’s Bio-Pharmaceutical strategy, supportive policies, pharmaceutical environment, talent pool, and growth space all meet with Curelong’s requirements,” stated Dr. De-Min Zhu, the co-founder and CEO of Curelong.
DBPIB has been part of National Zhongguancun Science Park since 2006. “Curelong’s establishment will greatly promote the nation-wide leading role of Zhongguancun Daxing Bio-Pharmaceutical Industry Base in the development of high quality medicines based on high technology and cutting-edge science,” stated Mr. Tian Dexiang, the Secretary of the Daxing District Working Committee and Director of DBPIB. “We will firmly provide Curelong with our full support in talent attraction, housing rent, project approval, and industrial land needs, along with other services.”
Based on the agreements, Curelong has leased a new 8800 square meters building (about 88,000 square feet) at DBPIB to set up the company’s nanomedicine pilot plant and quality control laboratory. DBPIB further provides Curelong with 20 acres of land for the construction of a research and development center and commercial production plant.
Curelong (Beijing) Pharmaceutical Co., Ltd., founded in 2017 at Beijing China, is a sister company with Cureport, a US company leading nanotechnology and nanomedicine development.